logo

Dova Pharmaceuticals, Inc. (DOVA)



Trade DOVA now with
  Date
  Headline
7/19/2019 7:39:12 AM Dova Pharmaceuticals Reports Commercial Availability Of DOPTELET
6/27/2019 8:11:08 AM Dova Pharma Announces FDA Approval Of SNDA For DOPTELET For Treatment Of Chronic Immune Thrombocytopenia
6/25/2019 8:10:05 AM Dova Pharma Announces European Union Marketing Authorization For DOPTELET For Thrombocytopenia In Patients With CLD
4/29/2019 7:34:55 AM Dova Pharma Gets Positive Opinion From CHMP For DOPTELET For Thrombocytopenia In Patients With Chronic Liver Disease
3/5/2019 7:12:58 AM Dova Pharma Q4 Net Loss $19.3 Mln Vs Loss Of $9.3 Mln Last Year
12/17/2018 7:34:10 AM Dova Pharmaceuticals Names David Zaccardelli President And CEO
11/5/2018 7:14:41 AM Dova Pharmaceuticals Announces FDA Acceptance Of SNDA For DOPTELET
9/27/2018 7:49:05 AM Dova Pharma And Salix Enter Into Exclusive Co-Promotion Agreement For DOPTELET
8/9/2018 4:12:45 PM Dova Pharmaceuticals Q2 Loss/share $0.70 Vs. Loss $0.32 Year Ago
6/25/2018 7:04:56 AM Nancy Wysenski Joins Dova Pharma’s Board Of Directors
6/4/2018 7:07:04 AM Dova Pharma Announces Publication Of Pivotal Phase 3 Data And Upcoming Congress Presentations For DOPTELET
5/21/2018 1:47:39 PM Dova Pharmaceuticals Announces U.S. FDA Approval Of DOPTELET